Prescribing information

 

Dr Yassir Javaid, GPwER in cardiology, presents a case study of a patient with HFrEF, and discusses their symptoms and how they could have been medically optimised sooner.

 

Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1

GPwER, GP with extended role;  HFrEF, heart failure with reduced ejection fraction.

 

Reference

  1. Entresto Summary of Product Characteristics, 2020. 
ENT20-C046j(1) July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]